Year : 2019  |  Volume : 22  |  Issue : 1  |  Page : 79--82

Bioprosthetic valve thrombosis in carcinoid heart disease

Kimberly Naden Hollander, Brijen L Joshi 
 Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA

Correspondence Address:
Kimberly Naden Hollander
1800 Orleans Street, Zayed 6208, Baltimore, MD 21287

Tricuspid regurgitation in carcinoid syndrome leads to significant morbidity and mortality that may warrant a tricuspid valve replacement. However, for patients with high serotonin levels and known hypercoagulable risks, the optimum timing for surgery and postoperative anticoagulation approaches remain unclear. High serotonin-triggered hypercoagulability makes prosthetic valves susceptible to thrombosis. Despite appropriate management with a somatostatin analog, some patients continue to have high markers of serotonin that causes platelet aggregation and rapid clot formation. In severely symptomatic patients who require valve surgery, it may not be feasible to postpone surgery until these metabolites are normalized, which may add a substantial risk for postoperative valve thrombosis to an otherwise uneventful procedure. In some, there is a significant need to predict and prevent bioprosthetic valve thrombosis in carcinoid heart disease and to identify best anticoagulation practices across a spectrum of its complex coagulation dynamics and clinical presentation.

How to cite this article:
Hollander KN, Joshi BL. Bioprosthetic valve thrombosis in carcinoid heart disease.Ann Card Anaesth 2019;22:79-82

How to cite this URL:
Hollander KN, Joshi BL. Bioprosthetic valve thrombosis in carcinoid heart disease. Ann Card Anaesth [serial online] 2019 [cited 2021 May 14 ];22:79-82
Available from:;year=2019;volume=22;issue=1;spage=79;epage=82;aulast=Hollander;type=0